Renal Artery Denervation in Chronic Heart Failure (REACH-Pilot)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01584700|
Recruitment Status : Completed
First Posted : April 25, 2012
Last Update Posted : August 23, 2016
Heart failure is a common condition with debilitating symptoms and a poor prognosis. Patients with heart failure have a massively overactive sympathetic nervous system which attempts to compensate for their poorly functioning heart. This ultimately has only detrimental effects.
One of the principle mediators for this sympathetic response is found in the nerve cells in the kidneys. Whilst a significant proportion of medications used to treat heart failure act on these harmful pathways, none target the kidney sympathetic-nerve cells specifically. Additionally, because of their multiple sites of action these drugs all have side effects.
A new procedure that has recently been developed for the treatment of high blood pressure is renal denervation. This involves inserting a small catheter through the femoral artery and passing it to the kidney artery under x-ray guidance. From there, using radiofrequency waves, the sympathetic nerves within the kidney can be destroyed.
The investigators anticipate that this procedure will have a significant positive effect on patients with heart failure and aim to perform a pilot safety study on 7 individuals with advanced heart failure to assess its safety and effectiveness. The investigators hypothesise that renal artery denervation will lead to significant clinical and biochemical improvements in patients with marked heart failure.
|Condition or disease||Intervention/treatment||Phase|
|Congestive Cardiac Failure||Procedure: Renal Artery Denervation||Phase 1|
One of the key physiological changes seen in heart failure patients is overactivity of the sympathetic nervous system. This is a homeostatic response produced by the body in an attempt to compensate for a poorly functioning heart and the resultant underperfused tissues. In acute heart failure this has a positive effect but in chronic heart failure, the long standing sympathetic overactivity causes multiple undesirable side effects including profound vasoconstriction, increased sodium reabsorption by the kidneys, renin release and decreased renal blood flow. Afferent and efferent sympathetic chains in the renal artery play an important role in the mediation of this response.
Current management of heart failure principally hinges on drugs that attempt to attenuate or interrupt this response via renin angiotensin system, adrenoreceptors or the renal tubules. These drugs have multiple side effects, partly because of their multiple sites of action. None directly target the sympathetic discharge at its source.
The development of renal artery denervation opens a unique opportunity for potentially longlasting relief of this intense renal sympathetic over-activity. The technique has a current role in the management of resistant hypertension where it has shown very favourable results with minimal side effects. The investigators envisage that this technique could also be highly beneficial to patients with heart failure by directly interrupting this sympathetic overactivity. This initial study involving 7 patients is a pilot safety study to assess this potential.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Renal Artery Denervation in Chronic Heart Failure- Pilot|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||July 2012|
Renal Artery Denervation
Procedure: Renal Artery Denervation
Radiofrequency ablation of the renal artery sympathetic outflow tract.
- Number of Participants with Adverse Events [ Time Frame: 1 year ]To ensure that patients with heart failure are able to acceptably tolerate the procedure and its potential effect on haemodynamics.
- NYHA classification [ Time Frame: 1 year ]To assess NYHA classification of dyspnoea
- 6 minute walk test [ Time Frame: 1 year ]To assess impact on 6 minute walk test
- Cardiopulmonary testing [ Time Frame: 1 year ]To assess the impact on cardiopulmonary exercise testing
- NT-proBNP [ Time Frame: 1 year ]To assess the impact on NT-proBNP levels
- Urinary excretion of renal hormones [ Time Frame: 1 year ]To assess the impact on the urinary excretion of renal hormones
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01584700
|London, United Kingdom, W120HS|
|St Mary's Hospital|
|London, United Kingdom, W21NY|
|Principal Investigator:||Justin E Davies, PhD||Imperial College London|